Share This Page
Suppliers and packagers for neoral
✉ Email this page to a colleague
neoral
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Novartis | NEORAL | cyclosporine | CAPSULE;ORAL | 050715 | NDA | Novartis Pharmaceuticals Corporation | 0078-0246-15 | 30 BLISTER PACK in 1 CARTON (0078-0246-15) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0078-0246-61) | 1995-07-14 |
| Novartis | NEORAL | cyclosporine | CAPSULE;ORAL | 050715 | NDA | Novartis Pharmaceuticals Corporation | 0078-0248-15 | 30 BLISTER PACK in 1 CARTON (0078-0248-15) / 1 CAPSULE, LIQUID FILLED in 1 BLISTER PACK (0078-0248-61) | 1995-07-14 |
| Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716 | NDA | Novartis Pharmaceuticals Corporation | 0078-0274-22 | 1 BOTTLE in 1 CARTON (0078-0274-22) / 50 mL in 1 BOTTLE | 1995-07-14 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Neoral (Cyclosporine)
Introduction
Neoral, a branded formulation of cyclosporine, is a critical immunosuppressant used primarily to prevent organ rejection post-transplantation and to treat certain autoimmune conditions like rheumatoid arthritis and psoriasis. Given its therapeutic importance, the supply chain for Neoral is tightly regulated, with a complex network of manufacturers, API (Active Pharmaceutical Ingredient) suppliers, and generics players. Understanding the landscape of suppliers for Neoral is essential for pharmaceutical companies, healthcare providers, and investors aiming to gauge supply stability, market competition, and potential risk factors.
Pharmaceutical Market Overview for Neoral
Neoral, marketed by Novartis, operates within a competitive environment featuring generic alternatives and biosimilars. While the original formulation uses a patented process, generic versions, containing cyclosporine, are produced by multiple manufacturers worldwide. The manufacturing ecosystem involves several stages—particularly API synthesis, formulation, and packaging—each with dedicated suppliers.
The primary driver lies in the supply chain for cyclosporine API, which forms the core component of Neoral. The original patent expired around 2010, leading to an influx of generic suppliers aiming to capture market share while maintaining quality standards required for immunosuppressants.
Key Suppliers of Cyclosporine API
1. AbbVie and Novartis (Original API Suppliers)
Historically, Novartis held proprietary rights, including control over initial API production processes. However, after patent expiry, the licensing and licensing-out arrangements led to multiple API manufacturers entering the market, including companies affiliated or licensed by Novartis.
2. Mylan / Viatris
Mylan, now part of Viatris, has been a notable supplier of cyclosporine API, offering both branded and generic formulations. Their manufacturing facilities adhere to cGMP standards, allowing broad distribution of cyclosporine API globally.
3. Sandoz (Novartis division)
Sandoz manufactures generic versions of cyclosporine, including API and finished formulations. Since Sandoz is a division of Novartis, it acts as an internal supplier in addition to external sources.
4. Hikurangi Bio
Hikurangi Bio, based in New Zealand, has expanded into the biosimilar and immunosuppressant API production sectors. They have achieved regulatory approval for multiple APIs, including cyclosporine, with supply agreements in several markets.
5. Rensource Biotech
An Indian-based manufacturer, Rensource Biotech specializes in immunosuppressants, including cyclosporine API, with a focus on the Asian and Middle Eastern markets.
6. Astellas Pharma
While primarily a pharmaceutical company producing immunosuppressants, Astellas also develops APIs and collaborates with manufacturing firms for supply. They hold rights to certain formulations but have expanded into API production for global distribution.
7. Teva Pharmaceutical Industries
Teva produces cyclosporine APIs and finished formulations, supplying both the generics market and branded drugs. Their API manufacturing complies with international standards, ensuring widespread availability.
Generic Manufacturers and Market Dynamics
The resurgence of generic cyclosporine sources has increased competition. As patent barriers have been diminished, a constellation of manufacturers from India, China, Eastern Europe, and other regions supply high-quality APIs, including:
- ChemiPharm (India)
- Synthon (Netherlands)
- Hexal (Germany)
- Biocon (India)
- Cipla (India)
These companies manufacture cyclosporine APIs for various formulations, including Neoral equivalents. Their supply reliability hinges on regulatory approvals, GMP compliance, and capacity expansion.
Regulatory and Quality Considerations
The complexity of ensuring therapeutic equivalence for immunosuppressants like Neoral places significant emphasis on API sourcing quality. Regulatory agencies, including the U.S. FDA and EMA, require strict GMP compliance and robust analytical validation. Many suppliers have achieved regulatory approvals, certifying their APIs meet pharmacopoeial standards, which is critical given the narrow therapeutic index of cyclosporine.
Supply Risks and Market Challenges
- Supply Chain Disruptions: Political instability, trade restrictions, and COVID-19 pandemic effects have periodically challenged API manufacturing and supply logistics.
- Regulatory Surveillance: Differences in regional approval processes can delay the introduction of generic APIs, affecting global supply.
- Price Fluctuations: Surging demand in emerging markets and capacity constraints can lead to price volatility, affecting the pricing strategies of Neoral products.
This landscape underscores the importance of diversified sourcing strategies to maintain supply continuity, especially as demand for immunosuppressants remains stable and potentially grows with expanding transplantation programs worldwide.
Beyond API: Final Formulation and Packaging Suppliers
While API supply delineates the primary sourcing, the manufacturing and packaging of Neoral involve specialized pharmaceutical firms. Novartis primarily oversees this process, but licensed contract manufacturing organizations (CMOs) in countries such as India, China, and Eastern Europe also play roles, especially for generic versions.
Conclusion
The supply landscape for Neoral is characterized by a diverse and global network of API manufacturers, many of which also produce generics of cyclosporine. Major players include Viatris (formerly Mylan), Sandoz, Teva, and regional manufacturers like Rensource Biotech, Hikurangi Bio, and others. As patents expired and markets liberalized, competition has intensified, leading to increased supply options but also requiring vigilant quality assurance and risk management.
To ensure a stable supply of Neoral, stakeholders must monitor regulatory developments, capacity expansions, and geopolitical factors influencing key API producers. The trend toward regional manufacturing and increased quality controls continues to shape the supply dynamics, making diversified sourcing essential for market stability.
Key Takeaways
- The primary API suppliers for Neoral are global players, including Viatris, Sandoz, Teva, and regional manufacturers from India and China.
- Post-patent expiration has expanded the number of approved API producers, increasing supply options but requiring rigorous quality oversight.
- Regulatory compliance with GMP standards remains critical due to the drug’s narrow therapeutic index.
- Supply chain resilience depends on sourcing diversification, especially amid geopolitical and pandemic-related disruptions.
- Contract manufacturing and packaging are often handled by regional CMOs, emphasizing the importance of comprehensive supplier vetting.
FAQs
1. Who are the main API manufacturers of cyclosporine for Neoral?
Major API producers include Viatris (formerly Mylan), Sandoz (Novartis division), Teva, Rensource Biotech (India), Hikurangi Bio (New Zealand), and regional firms like ChemiPharm and Cipla.
2. How has patent expiration affected the supplier landscape for Neoral?
Patent expiry around 2010 led to an influx of generic manufacturers, increasing supply options but also raising concerns over quality and manufacturing consistency.
3. What regulatory challenges do API suppliers face in producing cyclosporine?
Suppliers must meet GMP standards required by agencies like the FDA and EMA, given the drug’s narrow therapeutic window and critical immunosuppressive role.
4. Are there regional differences in sourcing for Neoral?
Yes. North American and European markets primarily rely on established suppliers like Teva and Sandoz, while Asian markets benefit from a broader array of regional manufacturers.
5. What risks should stakeholders monitor in the Neoral supply chain?
Risks include geopolitical instability, regulatory delays, manufacturing capacity issues, and pandemics disrupting logistics and production.
Sources:
[1] Novartis Annual Report 2022.
[2] U.S. Food and Drug Administration databases.
[3] European Medicines Agency approval records.
[4] Industry reports on immunosuppressant APIs.
[5] Public disclosures from Viatris, Teva, and regional manufacturers.
More… ↓
